Which has stronger valuation & earnings, VKTX or SANA?

Viking Therapeutics is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Viking Therapeutics N/A N/A -$359.64M -$4.66 N/A Sana Biotechnology N/A N/A -$244.17M -$0.76 N/A

Is VKTX or SANA more profitable?

Viking Therapeutics' return on equity of -94.56% beat Sana Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Viking Therapeutics N/A -94.56% -82.75% Sana Biotechnology N/A -103.02% -39.16%

Does the media refer more to VKTX or SANA?

In the previous week, Viking Therapeutics had 5 more articles in the media than Sana Biotechnology. MarketBeat recorded 9 mentions for Viking Therapeutics and 4 mentions for Sana Biotechnology. Viking Therapeutics' average media sentiment score of 0.64 beat Sana Biotechnology's score of 0.42 indicating that Viking Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viking Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Sana Biotechnology 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer SANA or LEGN?

In the previous week, Legend Biotech had 2 more articles in the media than Sana Biotechnology. MarketBeat recorded 6 mentions for Legend Biotech and 4 mentions for Sana Biotechnology. Legend Biotech's average media sentiment score of 0.44 beat Sana Biotechnology's score of 0.42 indicating that Legend Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sana Biotechnology 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Legend Biotech 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is AMLX or SANA more profitable?

Amylyx Pharmaceuticals' return on equity of -52.92% beat Sana Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Amylyx Pharmaceuticals N/A -52.92% -48.53% Sana Biotechnology N/A -103.02% -39.16%

Does the media refer more to AMLX or SANA?

In the previous week, Amylyx Pharmaceuticals had 6 more articles in the media than Sana Biotechnology. MarketBeat recorded 10 mentions for Amylyx Pharmaceuticals and 4 mentions for Sana Biotechnology. Sana Biotechnology's average media sentiment score of 0.42 beat Amylyx Pharmaceuticals' score of 0.29 indicating that Sana Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amylyx Pharmaceuticals 4 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sana Biotechnology 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is GRAL or SANA more profitable?

Sana Biotechnology has a net margin of 0.00% compared to GRAIL's net margin of -236.95%. GRAIL's return on equity of -15.88% beat Sana Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets GRAIL -236.95% -15.88% -14.02% Sana Biotechnology N/A -103.02% -39.16%

Does the media refer more to GRAL or SANA?

In the previous week, GRAIL had 10 more articles in the media than Sana Biotechnology. MarketBeat recorded 14 mentions for GRAIL and 4 mentions for Sana Biotechnology. GRAIL's average media sentiment score of 0.65 beat Sana Biotechnology's score of 0.42 indicating that GRAIL is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GRAIL 3 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sana Biotechnology 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, DYN or SANA?

Dyne Therapeutics is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dyne Therapeutics N/A N/A -$446.21M -$3.33 N/A Sana Biotechnology N/A N/A -$244.17M -$0.76 N/A

Is DYN or SANA more profitable?

Dyne Therapeutics' return on equity of -64.30% beat Sana Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Dyne Therapeutics N/A -64.30% -50.33% Sana Biotechnology N/A -103.02% -39.16%

Does the media refer more to DYN or SANA?

In the previous week, Dyne Therapeutics had 1 more articles in the media than Sana Biotechnology. MarketBeat recorded 5 mentions for Dyne Therapeutics and 4 mentions for Sana Biotechnology. Sana Biotechnology's average media sentiment score of 0.42 beat Dyne Therapeutics' score of 0.21 indicating that Sana Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dyne Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sana Biotechnology 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Sana Biotechnology (SANA) Competitors

$3.10 0.00 (0.00%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$3.09 -0.01 (-0.32%)

As of 09/18/2026 07:51 PM Eastern

Compare

SANA vs. VKTX, LEGN, AMLX, GRAL, and DYN

Should you buy Sana Biotechnology stock or one of its competitors? Sana Biotechnology's main competitors and comparable companies include Viking Therapeutics (VKTX), Legend Biotech (LEGN), Amylyx Pharmaceuticals (AMLX), GRAIL (GRAL), and Dyne Therapeutics (DYN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Sana Biotechnology compare to Viking Therapeutics?

Viking Therapeutics (NASDAQ:VKTX) and Sana Biotechnology (NASDAQ:SANA) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, media sentiment, institutional ownership, analyst recommendations and profitability.

Viking Therapeutics has a beta of 0.69, meaning that its stock price is 31% less volatile than the broader market. Comparatively, Sana Biotechnology has a beta of 2.12, meaning that its stock price is 112% more volatile than the broader market.

Viking Therapeutics is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.66	N/A
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.76	N/A

Viking Therapeutics presently has a consensus price target of $96.63, suggesting a potential upside of 233.30%. Sana Biotechnology has a consensus price target of $9.33, suggesting a potential upside of 201.08%. Given Viking Therapeutics' higher possible upside, research analysts plainly believe Viking Therapeutics is more favorable than Sana Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viking Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

In the previous week, Viking Therapeutics had 5 more articles in the media than Sana Biotechnology. MarketBeat recorded 9 mentions for Viking Therapeutics and 4 mentions for Sana Biotechnology. Viking Therapeutics' average media sentiment score of 0.64 beat Sana Biotechnology's score of 0.42 indicating that Viking Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viking Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Sana Biotechnology	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Viking Therapeutics' return on equity of -94.56% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viking Therapeutics	N/A	-94.56%	-82.75%
Sana Biotechnology	N/A	-103.02%	-39.16%

76.0% of Viking Therapeutics shares are held by institutional investors. Comparatively, 88.2% of Sana Biotechnology shares are held by institutional investors. 5.3% of Viking Therapeutics shares are held by insiders. Comparatively, 25.4% of Sana Biotechnology shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Sana Biotechnology beats Viking Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Sana Biotechnology compare to Legend Biotech?

Sana Biotechnology (NASDAQ:SANA) and Legend Biotech (NASDAQ:LEGN) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations, risk and media sentiment.

In the previous week, Legend Biotech had 2 more articles in the media than Sana Biotechnology. MarketBeat recorded 6 mentions for Legend Biotech and 4 mentions for Sana Biotechnology. Legend Biotech's average media sentiment score of 0.44 beat Sana Biotechnology's score of 0.42 indicating that Legend Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sana Biotechnology	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Legend Biotech	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Sana Biotechnology has a net margin of 0.00% compared to Legend Biotech's net margin of -7.21%. Legend Biotech's return on equity of -8.71% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sana Biotechnology	N/A	-103.02%	-39.16%
Legend Biotech	-7.21%	-8.71%	-5.40%

Sana Biotechnology has higher earnings, but lower revenue than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.76	N/A
Legend Biotech	$1.03B	3.32	-$296.80M	-$0.25	N/A

Sana Biotechnology currently has a consensus price target of $9.33, indicating a potential upside of 201.08%. Legend Biotech has a consensus price target of $53.14, indicating a potential upside of 201.78%. Given Legend Biotech's higher probable upside, analysts plainly believe Legend Biotech is more favorable than Sana Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Legend Biotech	1 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.47

88.2% of Sana Biotechnology shares are owned by institutional investors. Comparatively, 70.9% of Legend Biotech shares are owned by institutional investors. 25.4% of Sana Biotechnology shares are owned by insiders. Comparatively, 0.0% of Legend Biotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Sana Biotechnology has a beta of 2.12, indicating that its stock price is 112% more volatile than the broader market. Comparatively, Legend Biotech has a beta of 0.4, indicating that its stock price is 60% less volatile than the broader market.

Summary

Sana Biotechnology and Legend Biotech tied by winning 8 of the 16 factors compared between the two stocks.

How does Sana Biotechnology compare to Amylyx Pharmaceuticals?

Amylyx Pharmaceuticals (NASDAQ:AMLX) and Sana Biotechnology (NASDAQ:SANA) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and institutional ownership.

In the previous week, Amylyx Pharmaceuticals had 6 more articles in the media than Sana Biotechnology. MarketBeat recorded 10 mentions for Amylyx Pharmaceuticals and 4 mentions for Sana Biotechnology. Sana Biotechnology's average media sentiment score of 0.42 beat Amylyx Pharmaceuticals' score of 0.29 indicating that Sana Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amylyx Pharmaceuticals	4 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sana Biotechnology	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Amylyx Pharmaceuticals' return on equity of -52.92% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amylyx Pharmaceuticals	N/A	-52.92%	-48.53%
Sana Biotechnology	N/A	-103.02%	-39.16%

Amylyx Pharmaceuticals presently has a consensus target price of $38.86, suggesting a potential upside of 19.89%. Sana Biotechnology has a consensus target price of $9.33, suggesting a potential upside of 201.08%. Given Sana Biotechnology's higher probable upside, analysts clearly believe Sana Biotechnology is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amylyx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

Amylyx Pharmaceuticals has higher revenue and earnings than Sana Biotechnology. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amylyx Pharmaceuticals	$87.37M	41.33	-$144.74M	-$1.43	N/A
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.76	N/A

Amylyx Pharmaceuticals has a beta of -0.13, meaning that its share price is 113% less volatile than the broader market. Comparatively, Sana Biotechnology has a beta of 2.12, meaning that its share price is 112% more volatile than the broader market.

95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. Comparatively, 88.2% of Sana Biotechnology shares are held by institutional investors. 10.9% of Amylyx Pharmaceuticals shares are held by insiders. Comparatively, 25.4% of Sana Biotechnology shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Amylyx Pharmaceuticals and Sana Biotechnology tied by winning 7 of the 14 factors compared between the two stocks.

How does Sana Biotechnology compare to GRAIL?

GRAIL (NASDAQ:GRAL) and Sana Biotechnology (NASDAQ:SANA) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership.

Sana Biotechnology has lower revenue, but higher earnings than GRAIL. GRAIL is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GRAIL	$147.17M	24.52	-$408.35M	-$9.75	N/A
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.76	N/A

88.2% of Sana Biotechnology shares are owned by institutional investors. 1.8% of GRAIL shares are owned by company insiders. Comparatively, 25.4% of Sana Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

GRAIL currently has a consensus price target of $70.30, suggesting a potential downside of 12.96%. Sana Biotechnology has a consensus price target of $9.33, suggesting a potential upside of 201.08%. Given Sana Biotechnology's stronger consensus rating and higher possible upside, analysts clearly believe Sana Biotechnology is more favorable than GRAIL.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GRAIL	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

In the previous week, GRAIL had 10 more articles in the media than Sana Biotechnology. MarketBeat recorded 14 mentions for GRAIL and 4 mentions for Sana Biotechnology. GRAIL's average media sentiment score of 0.65 beat Sana Biotechnology's score of 0.42 indicating that GRAIL is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GRAIL	3 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sana Biotechnology	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

GRAIL has a beta of 3.25, meaning that its share price is 225% more volatile than the broader market. Comparatively, Sana Biotechnology has a beta of 2.12, meaning that its share price is 112% more volatile than the broader market.

Sana Biotechnology has a net margin of 0.00% compared to GRAIL's net margin of -236.95%. GRAIL's return on equity of -15.88% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GRAIL	-236.95%	-15.88%	-14.02%
Sana Biotechnology	N/A	-103.02%	-39.16%

Summary

Sana Biotechnology beats GRAIL on 10 of the 16 factors compared between the two stocks.

How does Sana Biotechnology compare to Dyne Therapeutics?

Dyne Therapeutics (NASDAQ:DYN) and Sana Biotechnology (NASDAQ:SANA) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

Dyne Therapeutics presently has a consensus target price of $32.17, suggesting a potential upside of 88.00%. Sana Biotechnology has a consensus target price of $9.33, suggesting a potential upside of 201.08%. Given Sana Biotechnology's higher possible upside, analysts plainly believe Sana Biotechnology is more favorable than Dyne Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyne Therapeutics	2 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.81
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

96.7% of Dyne Therapeutics shares are owned by institutional investors. Comparatively, 88.2% of Sana Biotechnology shares are owned by institutional investors. 9.5% of Dyne Therapeutics shares are owned by insiders. Comparatively, 25.4% of Sana Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Dyne Therapeutics is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.33	N/A
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.76	N/A

Dyne Therapeutics has a beta of 1.08, indicating that its stock price is 8% more volatile than the broader market. Comparatively, Sana Biotechnology has a beta of 2.12, indicating that its stock price is 112% more volatile than the broader market.

In the previous week, Dyne Therapeutics had 1 more articles in the media than Sana Biotechnology. MarketBeat recorded 5 mentions for Dyne Therapeutics and 4 mentions for Sana Biotechnology. Sana Biotechnology's average media sentiment score of 0.42 beat Dyne Therapeutics' score of 0.21 indicating that Sana Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dyne Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sana Biotechnology	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Dyne Therapeutics' return on equity of -64.30% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyne Therapeutics	N/A	-64.30%	-50.33%
Sana Biotechnology	N/A	-103.02%	-39.16%

Summary

Sana Biotechnology beats Dyne Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Sana Biotechnology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SANA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SANA vs. The Competition

Export

Metric	Sana Biotechnology	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$928.02M	$3.92B	$7.24B	$13.14B
Dividend Yield	N/A	3.65%	2.57%	12.30%
P/E Ratio	-4.08	14.30	275.79	25.40
Price / Sales	N/A	1,415.50	695.58	114.44
Price / Cash	N/A	110.75	77.42	51.66
Price / Book	5.17	15.45	10.46	6.33
Net Income	-$244.17M	-$22.86M	$3.49B	$358.33M
7 Day Performance	-0.96%	-1.21%	0.59%	1.12%
1 Month Performance	-24.39%	-4.42%	-2.01%	-2.67%
1 Year Performance	0.32%	37.81%	18.09%	6.01%

Sana Biotechnology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SANA Sana Biotechnology	2.8941 of 5 stars	$3.10 flat	$9.33 +201.1%	-5.8%	$928.02M	N/A	N/A	142	High Trading Volume
VKTX Viking Therapeutics	2.9716 of 5 stars	$31.53 -1.4%	$96.63 +206.5%	+11.3%	$3.73B	N/A	N/A	65
LEGN Legend Biotech	3.4955 of 5 stars	$18.53 -0.6%	$53.14 +186.8%	-49.9%	$3.61B	$1.27B	N/A	2,965	Analyst Downgrade
AMLX Amylyx Pharmaceuticals	3.8903 of 5 stars	$33.64 +6.4%	$36.50 +8.5%	+144.6%	$3.52B	$87.37M	N/A	136
GRAL GRAIL	0.8481 of 5 stars	$75.53 -0.9%	$71.11 -5.9%	+104.0%	$3.40B	$165.26M	N/A	910	News Coverage Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SANA) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sana Biotechnology (SANA) Competitors

SANA vs. VKTX, LEGN, AMLX, GRAL, and DYN

How does Sana Biotechnology compare to Viking Therapeutics?

Summary

How does Sana Biotechnology compare to Legend Biotech?

Summary

How does Sana Biotechnology compare to Amylyx Pharmaceuticals?

Summary

How does Sana Biotechnology compare to GRAIL?

Summary

How does Sana Biotechnology compare to Dyne Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SANA vs. The Competition

Sana Biotechnology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sana Biotechnology (SANA) Competitors

SANA vs. VKTX, LEGN, AMLX, GRAL, and DYN

How does Sana Biotechnology compare to Viking Therapeutics?

Which has more risk and volatility, VKTX or SANA?

Which has stronger valuation & earnings, VKTX or SANA?

Do analysts recommend VKTX or SANA?

Does the media refer more to VKTX or SANA?

Is VKTX or SANA more profitable?

Do institutionals & insiders hold more shares of VKTX or SANA?

Summary

How does Sana Biotechnology compare to Legend Biotech?

Does the media prefer SANA or LEGN?

Is SANA or LEGN more profitable?

Which has higher valuation and earnings, SANA or LEGN?

Do analysts prefer SANA or LEGN?

Do institutionals & insiders believe in SANA or LEGN?

Which has more volatility & risk, SANA or LEGN?

Summary

How does Sana Biotechnology compare to Amylyx Pharmaceuticals?

Does the media refer more to AMLX or SANA?

Is AMLX or SANA more profitable?

Do analysts rate AMLX or SANA?

Which has stronger valuation & earnings, AMLX or SANA?

Which has more risk & volatility, AMLX or SANA?

Do institutionals and insiders hold more shares of AMLX or SANA?

Summary

How does Sana Biotechnology compare to GRAIL?

Which has higher earnings and valuation, GRAL or SANA?

Do insiders and institutionals hold more shares of GRAL or SANA?

Do analysts recommend GRAL or SANA?

Does the media refer more to GRAL or SANA?

Which has more risk and volatility, GRAL or SANA?

Is GRAL or SANA more profitable?

Summary

How does Sana Biotechnology compare to Dyne Therapeutics?

Do analysts recommend DYN or SANA?

Do insiders & institutionals hold more shares of DYN or SANA?

Which has preferable valuation and earnings, DYN or SANA?

Which has more volatility and risk, DYN or SANA?

Does the media refer more to DYN or SANA?

Is DYN or SANA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SANA vs. The Competition

Sana Biotechnology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools